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INTRODUCTION
Early detection and correction of the risk factors for diabet-
ic nephropathy (DN) might slow the development or pro-
gression of DN. The urinary albumin excretion rate (AER)
is the mainstay in early detection of DN (1). In addition,
several factors such as hypertension, hyperglycemia, genetic
predisposition, retinopathy, age, dyslipidemia, family histo-
ry, smoking history, and the amount and origin of dietary
protein were also suggested as predictors of DN risk in indi-
vidual patients (1, 2). 
Cardiac autonomic neuropathy is an early and common com-
plication of diabetes mellitus (DM) (3). Previous studies have
reported that cardiac autonomic neuropathy might be a risk
factor for DN and associated with deterioration of renal func-
tion in people with DM (4-16). However, there are not enough
longitudinal data to show that cardiac autonomic neuropathy
could be an early predictor of deterioration of renal function
in normoalbuminuric, normotensive diabetics, especially in
patients with type 2 DM. The aim of our study, which was
performed retrospectively, was to evaluate whether cardiac
autonomic neuropathy, as an early complication of DM, is asso-
ciated with deterioration in glomerular filtration rate (GFR)
in normoalbuminuric, normotensive patients with type 2 DM.
MATERIALS AND METHODS
Patients
This retrospective longitudinal study was performed in
accordance with the principles of the 1983 Declaration of
Helsinki. From January 1996 to June 1997, consecutive
patients with type 2 DM, who had undertaken the cardiac
autonomic function test as one of the initial screening tests
of diabetic complications at the Samsung Medical Center,
Seoul, Republic of Korea, were eligible for inclusion if they
1) had systolic blood pressure of less than 130 mmHg and
diastolic blood pressure of less than 85 mmHg; 2) had a
urinary AER of less than 20 μ g/min; 3) had an initial serum
creatinine level noted at the time of the cardiac autonomic
function test and a follow-up serum creatinine level record-
ed at least 9 yr from that time; 4) had no evidence of cardiac
or renal disease at the time of the cardiac autonomic func-
tion test; and 5) had no history of antihypertensive medica-
tion at the time of the autonomic function test. Type 2 DM
was diagnosed if they 1) had no episodes of ketoacidosis; 2)
diagnosed DM after the age of 40 yr; 3) treated by diet alone,
or in combination with oral hypoglycemic agents or fasting
serum C-peptide values greater than 1.0 ng/mL in patients
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Cardiac Autonomic Neuropathy as a Predictor of Deterioration of the
Renal Function in Normoalbuminuric, Normotensive Patients with
Type 2 Diabetes Mellitus
Our study was performed to determine whether cardiac autonomic neuropathy can
predict deterioration of the renal function in normoalbuminuric, normotensive peo-
ple with type 2 diabetes mellitus (DM). One hundred and fifty-six normoalbuminuric,
normotensive people with type 2 DM were included in our retrospective longitudi-
nal study. We categorized normal patterns, early patterns, and definite or severe
patterns according to the results of the cardiac autonomic function test. Of 156
patients included, 54 had normal patterns, 75 had early patterns, 25 had definite
or severe patterns, and 2 had atypical patterns. During a median follow-up of nine
years, glomerular filtration rates (GFR) remained stable in the normal and early
pattern groups (mean changes, 4.50% and 0.77%, respectively) but declined in
those with definite or severe patterns (mean change, -10.28%; p=0.047). An abnor-
mal heart response to the deep breathing test of the cardiac autonomic function
tests was an independent predictor of GFR decline. Our data suggest that cardiac
autonomic neuropathy, especially with a definite or severe pattern, might be asso-
ciated with a subsequent deterioration in renal function in normoalbuminuric, nor-
motensive people with type 2 DM.
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When multiple follow-up creatinine levels were available,
we used the most recent value, and excluded values that were
associated with an acute illness or hospitalization. One hun-
dred and 56 patients met the inclusion criteria.
Cardiac autonomic function tests
We conducted five tests for each patient to evaluate car-
diac autonomic function. Three tests to assess parasympa-
thetic neuropathy were heart-rate response to deep breath-
ing, standing up and the Valsalva manoeuvre. Two tests to
assess sympathetic neuropathy were blood-pressure response
to sustained handgrip and standing up. The methods of each
test are described below (17).
Heart-rate response to deep breathing
Six maximal expirations and inspirations were performed
within one minute in the supine position, during which heart
rate was continuously recorded by electrocardiography (ECG),
and the R-R intervals were recorded. The E/I ratio was cal-
culated as the mean of the longest R-R interval during expi-
ration (E) divided by the mean of the shortest R-R interval
during inspiration (I). ‘Abnormal’ was defined as a ratio of
less than 1.00; ‘borderline’ as a ratio of 1.01-1.09; and ‘normal’
as a ratio of more than 1.11.
Heart-rate response to standing up 
The patient lay quietly and stood up unaided. The heart
rate was recorded continuously by ECG. The ‘30:15 ratio’,
which is the ratio of the longest R-R interval (around the
30th beat after starting to stand up) to the shortest R-R inter-
val (around the 15th beat), was then calculated. ‘Abnormal’
was defined as a ratio of less than 1.00; ‘borderline’ as a ratio
of 1.01-1.03; and ‘normal’ as a ratio of more than 1.04. 
Heart-rate response to the Valsalva manoeuvre
The patient sat quietly and then blew into a mouthpiece
at a pressure of 40 mmHg for 15 sec. Heart rate was record-
ed continuously using ECG during and after the manoeuvre.
The ratio of the longest R-R interval shortly after the manoeu-
vre to the shortest R-R interval during the manoeuvre was
then calculated. ‘Abnormal’ was defined as a ratio of less
than 1.10; ‘borderline’ as a ratio of 1.11-1.20; and ‘normal’
as a ratio of more than 1.21.
Blood-pressure response to sustained handgrip
The patient squeezed a handgrip dynamometer as hard as
possible for a few seconds and then maintained steady pres-
sure at 30% of the maximum pressure for three to four min-
utes. Blood pressure was measured each minute, and the dif-
ference between the diastolic blood pressure before starting
and that just before the release of the handgrip was measured.
‘Abnormal’ was defined as a difference of less than 10 mmHg;
‘borderline’ as a difference of 11-15 mmHg; and ‘normal’ as
a difference of more than 16 mmHg.
Blood-pressure response to standing up 
Blood pressure was measured while the patient was lying
down and again one minute after standing up, and the dif-
ference in systolic blood pressure was noted. ‘Abnormal’ was
defined as a difference of more than 30 mmHg; ‘borderline’
as a difference of 11-29 mmHg; and ‘normal’ as a difference
of less than 10 mmHg.
Classification of test result
We categorized the results of these five tests as: ‘normal
pattern’, all tests normal or one borderline; ‘early pattern’,
one of the three heart-rate tests abnormal or two borderline;
‘definite or severe pattern’, two or more of the three heart-
rate tests abnormal (definite pattern), or definite pattern plus
one or both of the blood-pressure results abnormal, or both
borderline (severe pattern); ‘atypical pattern’, any other com-
bination of abnormal tests.
Clinical information and laboratory data 
Clinical information was assessed from written and electron-
ic medical records, which included medical history, current
medications and laboratory data. The data collected includ-
ed age, sex, urinary AER, serum creatinine, systolic blood
pressure, diastolic blood pressure, retinopathy, glycosylated
hemoglobin level (HbA1c), total cholesterol level, high-den-
sity lipoprotein (HDL) cholesterol level, low-density lipopro-
tein (LDL) cholesterol level, triglycerides level, homeostasis
model for insulin resistance (HOMA-IR), body fat mass (%),
use of statin, use of aspirin, duration of diabetes and estimated
GFR. Urinary AER was assessed on 24 hr urine collection.
Normoalbuminuria was defined as less than 20 μ g/min in 2
out of 3 consecutive tests taken within 2-3 months. Blood
pressure was measured twice, 5 min apart, using a random
zero sphygmomanometer with the patient seated after 10
min of rest. Based upon the average of readings at each of
two or more visits, hypertension was defined as a systolic
blood pressure of more than 140 mmHg and/or a diastolic
blood pressure of more than 90 mmHg for three months
and/or the commencement of antihypertensive therapy. The
presence of retinopathy was assessed by fundus photography,
which was interpreted by ophthalmologist. HOMA-IR (%),
index of insulin resistance, was calculated by the formula,
fasting glucose/18×insulin/22.5, with insulin expressed in
μ U/mL and fasting glucose in mg/dL (18). Body fat mass
(%) was measured in a bioimpedance analysis (Inbody 2.0,
Biospace, Seoul, Korea). Estimated GFR was calculated using
the Modification of Diet in Renal Disease four-variable equa-
tion at the time of the cardiac autonomic function test (19).
During the follow-up period, we also calculated estimated
S70 Y.K. Kim, J.E. Lee, Y.G. Kim, et al.glomerular filtration rate (eGFR) using the chemistry profile
at the last visit.
Statistical analysis
Demographic, clinical, and biochemical data are expressed
as means±SD. We used a paired t test to compare differences
in continuous variables within the groups. One-way ANOVA
test or Kruskal-Wallis test was used to compare differences in
continuous variables, and the chi-square test or Fisher’s exact
test to compare categorical variables among groups. The asso-
ciation of the change of eGFR with demographic, clinical or
biochemical variables were determined using univariate lin-
ear regression analysis. Multivariate linear regression analy-
ses were conducted to detect independent predictors of eGFR
decline. Kaplan-Meier life-table analysis was used to calculate
the cumulative incidence of hypertension during follow-up
period. A p value of <0.05 was considered statistically sig-
nificant. All statistical analyses were performed with SPSS
12.0 for Windows (SPSS, Chicago, IL, U.S.A.).
RESULTS
Of 156 patients, 54 had normal patterns on the autonom-
ic function test, 75 had early patterns, 25 had definite or
severe patterns, and 2 had atypical patterns. The prevalence
of cardiac autonomic neuropathy was 65.4% in normoalbu-
minuric, normotensive stage. Forty-one patients had concor-
dant abnormal heart-rate response to deep breathing, 59 con-
cordant abnormal heart-rate response to standing up, 29 con-
cordant abnormal heart-rate response to the Valsalva manoeu-
vre, 6 concordant abnormal blood-pressure response to sus-
tained handgrip and no patient concordant abnormal blood-
pressure response to standing up. Two patients with atypi-
cal patterns were eliminated from the analysis because their
number was too small to obtain statistically valid results. The
characteristics of the patients, based on their patterns of auto-
nomic function are given in Table 1. There were no signifi-
cant differences in sex, serum creatinine, eGFR, urinary AER,
systolic and diastolic blood pressure, HbA1c, retinopathy,
lipid profiles and body fat mass at baseline among the three
groups. There were also no significant differences in numbers
of patients with treatment with statin and aspirin among
the groups. However, the definite or severe pattern group
was older and had DM longer than the other groups. HOMA-
IR values in the early pattern group were significantly high-
er than those in the normal pattern group.
Median follow-up duration was 9 yr. During the follow-
up period, there was no significant difference between the
baseline eGFR and the last follow-up eGFR in the normal
pattern and early pattern groups. However, in the definite
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Normal pattern (n=54) Early pattern (n=75)
Definite or severe 
pattern (n=25)
Age (yr) 53.4±8.0 55.3±9.1 58.6±8.8*
Sex (% male) 34 (63.0) 33 (44.0) 13 (52.0)
Duration of diabetes (yr) 6.75±5.42 7.39±6.00 10.08±6.18*
UAE (μ g/min) 5.65±4.10 7.16±5.20 5.75±3.35
Serum creatinine (mg/dL) 0.95±0.15 0.92±0.17 0.90±0.14
eGFR (mL/min/1.73 m
2) 81.04±12.38 79.32±14.88 82.66±16.41
Systolic BP (mmHg) 119.94±11.23 116.40±11.37 119.04±10.11
Diastolic BP (mmHg) 68.17±7.28 66.83±8.00 67.48±9.22
Retinopathy 9/49 (18.4%) 23/69 (33.3%) 6/22 (27.3%)
HbA1c 8.15±2.09 8.64±2.05 8.27±1.70
Hemoglobin (g/dL) 14.6±1.6 14.4±1.4 14.2±1.3
Hematocrit (%) 42.0±5.0 41.5±3.7 40.0±5.7
Serum cholesterol (mg/dL) 197.00±37.04 198.80±31.05 188.88±41.71
HDL cholesterol (mg/dL) 49.94±15.30 54.10±43.98 47.63±22.19
LDL cholesterol (mg/dL) 115.39±29.61 124.83±30.52 115.55±36.05
Triglycerides (mg/dL) 130.71±69.45 134.83±72.20 146.25±182.78
HOMA-IR 2.12±1.40 3.10±2.92* 2.10±1.18
Body fat mass (%) 21.5±7.5 23.4±7.0 22.3±9.2
Use of ACEI or ARB 14 32 7
Use of statin (%) 3 (5.6%) 2 (2.7%) 1 (4.0%)
Use of aspirin (%) 0 (0%) 6 (8%) 2 (8%)
Follow-up duration 9.40±0.50 9.33±0.47 9.48±0.51
Table 1. Clinical and laboratory features at baseline and cardiac autonomic function
*p<0.05 compared with those whose autonomic neuropathy was normal pattern.
UAE, urinary albumin excretion; eGFR, estimated glomerular filtration rate; BP, blood pressure; HbA1c, glycosylated haemoglobin; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; HOMA-IR, homeostasis model for insulin resistance; ACEI, angiotensin converting enzyme inhibitor; ARB,
angiotensin receptor blocker. or severe pattern group, eGFR decreased significantly. In an
intergroup comparison, the definite or severe pattern group
had a greater change in eGFR than that of the normal pat-
tern group or early pattern group (Table 2).
Predictors of a decline in renal function
Table 3 shows the univariate analyses for relationship of
the change of eGFR with clinical parameters at baseline of
the study. The decline in eGFR was associated with an abnor-
mal heart-rate response to the deep breathing test, age, eGFR,
total serum cholesterol level and diabetic retinopathy. Sixty-
two patients progressed to hypertension during the follow-
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Group differences, normal pattern vs. early pattern (p=0.354).
*Group differences, normal pattern vs. definite or severe pattern (p=
0.007); 
� Group differences, early pattern vs. definite or severe pattern
(p=0.035).
eGFR, estimated glomerular filtration rate.
Autonomic
neuropathy
% GFR
change from
baseline
p
eGFR (mL/min/1.73 m
2)
Baseline Follow-up
Normal pattern 81.04±12.38 84.42±17.63 4.50±17.78 0.092
Early pattern 79.32±14.88 79.32±21.10 0.77±24.30 1.000
Definite or   82.66±16.41 72.25±20.92 -10.28±25.77*,�0.047
severe pattern
Table 2. Cardiac autonomic neuropathy and glomerular filtra-
tion rate changes 
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Fig. 1. Cumulative incidence of the development of hypertension
in 154 initially normoalbuminuric, normotensive people with type
2 diabetes over a nine-year follow-up.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin recep-
tor blocker; UAE, urinary albumin excretion; eGFR, estimated glomerular
filtration rate at baseline; HbA1c, glycosylated haemoglobin; HOMA-IR,
homeostasis model for insulin resistance.
Categorical 
variables
p
value
% eGFR change from
baseline
Variable 
present
Variable 
absent
Abnormal heart-rate response  -14.0±30.2 5.4±17.0 <0.001
to deep breathing test (n=41)
Abnormal heart-rate response  1.2±20.8 -0.3±24.2 0.686
to standing up (n=59)
Abnormal heart-rate response  -3.9±26.6 1.3±22.0 0.282
to Valsalva manoeuvre (n=29)
Abnormal blood-pressure  -13.0±18.3 0.8±23.0 0.150
response to sustained 
handgrip (n=6)
Male sex (n=80) -0.3±20.2 0.9±25.6 0.746
Retinopathy (n=38) -12.1±25.2 5.7±18.8 <0.001
Use of ACEI or ARB -9.3±27.8 -0.7±26.3 0.392
Use of statin (n=6) 8.1±16.0 -0.0±23.1 0.394
Use of aspirin (n=8) -14.5±34.5 1.1±22.0 0.061
New-onset hypertension (n=62) -8.0±27.5 5.9±17.2 0.001
Age -0.244 0.002
UAE -0.097 0.234
eGFR -0.225 0.005
Systolic blood pressure -0.093 0.251
Diastolic blood pressure 0.096 0.236
HbA1c -0.114 0.160
Total serum cholesterol -0.225 0.005
HOMA-IR -0.114 0.204
Body fat mass 0.038 0.651
Duration of diabetes -0.098 0.224
Table 3. Univariate analyses for relationship of the change of
eGFR with clinical parameters at baseline of study
Continuous variable Correlation coefficient p value
UAE, urinary albumin excretion; eGFR, estimated glomerular filtration
rate at baseline; HbA1c, glycosylated haemoglobin; HOMA-IR, home-
ostasis model for insulin resistance.
t β p value
Abnormal heart-rate response  -0.196 -2.11 0.038
to deep breathing test
Abnormal heart-rate response 0.148 1.63 0.108
to standing up
Abnormal heart-rate response 0.088 1.03 0.307
to Valsalva manoeuvre
Abnormal blood-pressure response -0.180 -1.99 0.051
to sustained handgrip 
Age -0.194 -2.04 0.045
Male sex 0.047 0.32 0.747
UAE 0.021 0.24 0.811
eGFR -0.175 -1.76 0.082
Systolic blood pressure -0.086 -0.87 0.388
Diastolic blood pressure 0.121 1.23 0.222
Retinopathy -0.366 -4.22 <0.001
HbA1c -0.144 -1.36 0.177
Total serum cholesterol -0.165 -1.76 0.081
HOMA-IR -0.118 -1.27 0.209
Body fat mass 0.056 0.36 0.722
New-onset hypertension -0.308 -3.34 0.001
Duration of diabetes 0.119 1.31 0.192
Table 4. Multiple linear regression analysis for the significance
of the relationship between the change of eGFR and cardiac
autonomic neuropathy after adjustment for other variablesup period. Seventeen of the 54 patients with normal pattern
of cardiac autonomic neuropathy progressed to hypertension,
as did 36 of the 75 patients who had an early pattern and 9
of the 25 patients who had a definite or severe pattern. There
was no significant difference in the incidence of the develop-
ment of hypertension among the different patterns of cardiac
autonomic neuropathy (Fig. 1). However, new-onset hyper-
tension during the follow-up period was associated with the
decline in eGFR (Table 3, 4). Multivariate linear regression
analysis was conducted to determine the independent pre-
dictors affecting the decline of eGFR. The heart-rate response
to the deep breathing test, age, diabetic retinopathy and new-
onset hypertension during follow-up period were independent-
ly and significantly related to the decline in eGFR (Table 4). 
DISCUSSION
Previous studies have demonstrated a significant relation-
ship between cardiac autonomic neuropathy and decline in
GFR in individuals with DM (4-12). Previous studies also
showed that cardiac autonomic neuropathy is one of the early
complications of DM and exists even at the normoalbumin-
uric, normotensive stage (3, 4). There are few longitudinal
data that demonstrate whether cardiac autonomic neuropa-
thy has a close relationship to the deterioration of renal func-
tion in the normoalbuminuric, normotensive stage. In our
study, we enrolled 156 subjects with type 2 DM with nor-
moalbuminuria and normotension at the baseline and fol-
lowed up for about 9 yr retrospectively. The results showed
that the prevalence of cardiac autonomic neuropathy was
65.4% and cardiac autonomic neuropathy was one of the sig-
nificant predictors of decline in renal function in normoten-
sive, normoalbuminuric subjects.
The underlying mechanism by which cardiac autonomic
neuropathy may lead to nephropathy is reported in previous
studies (11-16). If sympathetic neuropathy is dominant, renal
sodium excretion and renal blood flow are diminished, and
the GFR is decreased via vasoconstriction in the kidney. If
parasympathetic neuropathy is dominant, systolic hyperten-
sion, resting tachycardia, and increased cardiac output devel-
op, which injure the glomerular membrane, causing an in-
crease in albumin leakage through the glomerular membrane.
Our study showed that parasympathetic neuropathy (i.e.,
abnormal heart-rate response to the deep breathing test) affect-
ed GFR whereas sympathetic neuropathy did not. This find-
ing may be related to the small number of patients with sym-
pathetic neuropathy in our study, which showed the low
prevalence (3.9%) of sympathetic neuropathy in the nor-
moalbuminuric, normotensive stage. A large number of sub-
jects with sympathetic neuropathy or 24-hr ambulatory blood
pressure monitoring-instead of blood pressure response to
sustained handgrip and blood-pressure response to standing
up-will clarify the relationship of sympathetic neuropathy
with a deterioration of renal function (14-16).
In our study, in addition to abnormal heart-rate response
to the deep breathing test, age and diabetic retinopathy were
also independent and significant risk factors for a decline in
GFR. These findings are similar with previous study, which
reported that baseline plasma creatinine, systolic blood pres-
sure, age at diagnosis, height, Indian-Asian ethnicity, ever
smoking, previous retinopathy, and urinary albumin were
independently associated with increased risk of development of
reduced creatinine clearance in patient with type 2 DM (20).
The baseline levels of HbA1c were relatively high among
three groups in our study because patients with naive type
2 DM and high blood glucose level were also enrolled. But
the levels of HbA1c were not associated with a deterioration
of renal function and decreased equally with treatment dur-
ing the follow-up period.
The cumulative incidence of development of hypertension
was 37% during the follow-up period. Previous study report-
ed that Cardiac autonomic neuropathy is independently asso-
ciated with hypertension in normoalbuminuric Type 2 dia-
betic patients with no history of hypertension (21). In our
study, there was no significant difference in the incidence of
the development of hypertension among the different pat-
terns of cardiac autonomic neuropathy. Larger prospective
study will clarify the relationships between cardiac autonom-
ic neuropathy and hypertension in patients with type 2 DM.
In our study, although there was no significant difference in
microalbuminuria between the patients with new-onset hyper-
tension and without new-onset hypertension (7.0±5.0 μ g/
min vs. 6.0±4.3 μ g/min, p=0.180), eGFR decreased sig-
nificantly in patients with new-onset hypertension compared
with the patients without new-onset hypertension (% eGFR
change from baseline, -8.0±27.5 vs. 5.9±17.2, p=0.001).
New-onset hypertension during the follow-up period was
an independent and significant risk factor for a decline in
GFR.
In our study, 53 of the 62 patients with hypertension dur-
ing the follow-up period were treated with angiotensin con-
verting enzyme inhibitor (ACEI) or angiotensin receptor
blocker (ARB). The use of ACEI or ARB was not associated
with change of eGFR, which is different from previous stud-
ies (22, 23). Twenty-six of 53 patients prescribed ACEI or
ARB took more than two anti-hypertensive agents and all
of 9 patients who were not prescribed ACEI or ARB took
only one anti-hypertensive agent that may be why the use
of ACEI or ARB did not conferred significant renal benefit in
our study.
Previous data reported that diabetic parasympathetic neu-
ropathy affects the insulin resistance in type 2 diabetic pati-
ents (24). In our study, HOMA-IR, an index of insulin resis-
tance, was higher in group with an early pattern than in the
group with a normal pattern. However, HOMA-IR had no
significant relationship with eGFR decline. 
The results of our study revealed that cardiac autonomic
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. .neuropathy was an important predictor of decline in GFR,
however, risk factors that were not analyzed in our study
should be also considered. Development of microalbumin-
uria or control of hyperglycemia during follow-up period
may affect decline in GFR. We could not exclude the poten-
tial role of these factors in deterioration of renal function dur-
ing follow-up period. And our study was performed retro-
spectively so there were quite heterogeneous patients among
three groups, in particular in terms of duration of diabetes
and patient’s age, which was one of the limitations of our
study. Therefore, we cautiously conclude that cardiac auto-
nomic neuropathy may be considered as one of the risk fac-
tors in deterioration of the renal function in normoalbumin-
uric, normotensive patients with type 2 diabetes mellitus. 
In conclusion, cardiac autonomic neuropathy could be pre-
sent at the normoalbuminuric, normotensive stage. Cardiac
autonomic dysfunction could be associated with deteriora-
tion of GFR in normoalbuminuric, normotensive patients
with type 2 DM and may be an early predictor of DN. 
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